Hi ,

Latest Videos From SynBioBeta 2024:

• The Molecular Engines of Metabolism: Drew Berry presented the molecular mechanisms that power your cells and tissues, converting food and air into the flow of chemical energy that makes your body alive. Exploiting the incredible advances in video game technology, vast molecular landscapes can be generated upon a foundation of scientific research. Enabling interactive exploration of dynamic molecular biology in ultra-high resolution detail, accessible and illuminating science education delivered via student mobile technology.

  
  

  Navigating the Investment Ecosystem: De-risking SynBio Ventures for Trend-Savvy Investors. In this dynamic session, we merge the foresight of investment trends with the strategic insight required to de-risk synthetic biology ventures. From understanding the intricacies of regulatory landscapes to mastering the art of communicating value propositions, this session promises a deep dive into how startups can align with investor expectations and navigate the complexities of capital acquisition in a landscape ripe with opportunity and challenge. 
  

 Discover how synthetic biology transforms industries such as healthcare, food, agriculture, environment, consumer goods, chemicals, materials, and more. Our flagship conference showcases the latest breakthroughs and trends in the field. Join us at SynBioBeta, May 5-8, 2025, and be part of the bio revolution! Register before conference pass pricing increases Friday, July 26.

At SynBioBeta, we are passionate about harnessing the power of biology to create transformative solutions for a better world. We can help you reach the full spectrum of synthetic biology professionals across a suite of media platforms. Download our 2024-2025 Media Kit

Insights:

• ZymoChem Fuses Enzymes and Chemistry to Revolutionize the Hygiene Industry. The company introduces the world's first scalable, 100% bio-based, and biodegradable super absorbent polymer, revolutionizing the hygiene industry and combating microplastics.
  

• Building A Durable Bioeconomy Demands New Mindsets and Approaches. Building a thriving bioeconomy requires strong partnerships between industry and government and creating a modern ecosystem focused on accelerated commercialization.

Industry News:

• Eligo Bioscience Achieves Breakthrough in In Vivo Bacterial Genome Editing: Published in the journal Nature, Eligo's work demonstrates for the first time the ability to precisely and efficiently edit the genomes of bacteria directly within the gut, achieving nearly 100% efficiency without disturbing surrounding microbial communities.

• Harnessing Bacteriophage as a New Weapon Against Acute GVHD: New research uncovers the potential of endolysin enzyme in combating multidrug-resistant infections in allo-HCT patients.

• Aspect Biosystems Secures $72.75 Million Government Investment to Advance Bioprinted Tissue Therapeutics. Aspect Biosystems is at the forefront of bioprinted tissue therapeutics, developing treatments designed to replace, repair, or supplement biological functions in the body.

• Briefly Bio Launches to Tackle Reproducibility Crisis in Science: With this launch, Briefly Bio has also secured a $1.2 million pre-seed funding round led by Compound VC, with participation from NP-Hard, Tiny VC, and various angel investors from the tech and biotech sectors.

• Syngenta and Ginkgo Bioworks Forge New Collaboration to Fast-Track Biological Solutions: This partnership marks a significant step forward in developing sustainable agricultural solutions, combining Syngenta's innovation in crop protection with Ginkgo's cutting-edge capabilities in biological engineering.

• bitBiome Welcomes Industry Veteran John Nicols as Strategic Advisor to Propel Enzyme Product Development: John Nicols is also our Track Chair for the 2025 SynBioBeta Conference for Chemicals and Materials.

John Nicols speaking at SynBioBeta.

Additional Industry News:

• Learn how synbio is poised to revolutionize the industry and drive sustainable solutions: GeneOnline presents an exclusive interview with Dr. John Cumbers, Founder and CEO of SynBioBeta, about the potential of synthetic biology in addressing biopharma inefficiencies, improving healthcare access, and combating climate change.

• The SynBioBeta Meeting Is Growing Up, and So Is DNA Synthesis by Jason T. Gammack, Chief Executive Officer at Ansa Biotechnologies.

• SynBioBeta Recap: GenAI transforming synthetic biology into digital biology. The promise of AI and digital biology dominated discussions at SynBioBeta 2024.

Regards

Jeff

Jeffrey S. Buguliskis, PhD

Director of Content, SynBioBeta

Who's hiring?

• Head of Informatics at Colorifix (Norwich or Cambridge)

• Synthetic Biology Researcher – Developer (Term BioNet Fellow) at MITRE (US)

• Associate Account Executive at LatchBio (San Francisco, CA) 

• Head of Operations at NewLimit (South San Francisco, CA)

• Group Leader, Metabolism at NewLimit (South San Francisco, CA)